Abbisko Cayman announced Wednesday that its Shanghai-based subsidiary, Abbisko Therapeutics, has formed a strategic research collaboration and licensing agreement with pharmaceutical giant Eli Lilly.
Under the terms of the deal, both companies will work together on the discovery and development of new treatments across a range of targets. As part of the arrangement, Abbisko Therapeutics could receive milestone payments totaling as much as $1.9 billion, tied to development, regulatory, and commercial achievements.
